Flagship Biosciences
Flagship Biosciences provides a comprehensive suite of genomic and pathology services, utilizing proprietary AI software and advanced technologies to support oncology, immune-oncology, and rare disease research.
Services
Flagship Biosciences offers a comprehensive set of discovery, translational, and clinical testing services, as well as assay development. The company has domain expertise in oncology, immune-oncology, neuromuscular disorders, and cell and gene therapies for rare diseases. They provide a range of genomic analysis services including full genome sequencing, RNA sequencing, spatial transcriptomics, and methylation sequencing. Their consultative approach to data science integrates results from spatial proteomic and genomic data to deliver customized solutions.
Proprietary Technology
Flagship Biosciences utilizes its proprietary artificial intelligence software, Flotilla, to provide customized deep-learning solutions in digital pathology and image analysis. Their state-of-the-art digital pathology and image analysis department is backed by seventeen US patents and supports multiplex IHC, FISH, and CISH assays capable of detecting up to six biomarkers per sample. Additionally, they employ the NanoString GeoMx® Digital Spatial Profiler for spatial, highly multiplexed tissue profiling.
Genomic and Proteomic Platforms
Flagship Biosciences offers an extensive range of automated staining platforms including Ventana BenchMark ULTRA, Ventana DISCOVERY ULTRA, Leica Biosystems BOND RX, and Dako Autostainer Link 48. They provide an extensive library of validated singleplex, duplex, and multiplex panels for client use and employ the Luminex FLEXMAP 3D® system to create custom panels that track up to 500 analytes in a single sample. The company also has next-generation sequencing capabilities using Illumina® systems like NovaSeq™ 6000 and NovaSeq™ X Plus.
Partnerships
Flagship Biosciences partners with Genomenon® to offer clients access to Genomenon's rare disease and oncology genetics library. They also utilize NanoString's nCounter® Pro Analysis System for gene expression studies, capable of multiplexing up to 800 targets in a single reaction. These collaborations enhance their comprehensive service offerings, supporting a range of genomic and proteomic analyses.
FDA Collaboration
Flagship Biosciences has a proven track record of successful interactions with the FDA, ensuring therapeutic success. They provide fluorescence in situ hybridization (FISH) testing for identifying sub-microscopic chromosomal structural rearrangements, variants, and low-frequency abnormalities. This includes comprehensive karyotyping and G-Banding services on various sample types, such as bone marrow, peripheral blood, and lymph nodes. Their CLIA-validated test panels support a full work-up on lymphoid and myeloid malignancies, reflecting their adherence to stringent regulatory standards.